Newswire (Published: Tuesday, March 12, 2019, Received: Tuesday, March 12, 2019, 5:19:53 PM CDT)

Word Count: 350

2019 MAR 12 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Daily -- Current study results on Oncology - Prostate Cancer have been published. According to news reporting from Aurora, Colorado, by NewsRx journalists, research stated, “Prostate cancer is one of the most common cancers in the United States, with an estimated incidence of 164,690 cases, accounting for 9.5% of all new cancer diagnoses. The mainstay of therapy for metastatic prostate cancer involves suppressing testosterone production through androgen deprivation therapy.”

The news correspondents obtained a quote from the research from the University of Colorado, “However, nearly all patients on androgen deprivation therapy will develop resistance to hormone therapy. An improved understanding of the biology of castration resistance has allowed for the development of novel inhibitors of the androgen axis. Agents such as abiraterone acetate, which provides additional androgen suppression by inhibiting cytochrome P450 17A (CYP17A), have improved survival outcomes of patients with advanced prostate cancer. The longest experience with abiraterone acetate is in the metastatic castration-resistant setting. However, more recent trials have demonstrated that abiraterone acetate is an option for treatment earlier in the prostate cancer paradigm.”

According to the news reporters, the research concluded: “This review will cover the current use of abiraterone acetate in combination with prednisone for the treatment of castration-resistant prostate cancer.”

For more information on this research see: Abiraterone Acetate To Treat Metastatic Castration-resistant Prostate Cancer In Combination With Prednisone. DRUGS OF TODAY, 2019;55(1):5-15. DRUGS OF TODAY can be contacted at: Prous Science, Sau-Thomson Reuters, 398 Provenca, 08025 Barcelona, Spain.

Our news journalists report that additional information may be obtained by contacting A. Jimeno, University of Colorado, Canc Center, Dept. of Med, Div Med Oncol, Aurora, CO 80045, United States.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1358/dot.2019.55.1.2914339. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)

Companies

University of Colorado

Places

North America
Southern Europe
Spain
United States
Americas
Europe
Province of Barcelona
Colorado
Barcelona
Aurora

Subjects

Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research